Amirhossein Ahmadieh Yazdi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Amirhossein Ahmadieh Yazdi has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Hamed Manoochehri
The Persian Gulf Marine Biotechnology Research Center, The Persian Gulf Biomedical Sciences Research Institute, Bushehr University of Medical Sciences, Bushehr, Iran
2 shared publications - Hamid Tanzadehpanah
Metabolic Syndrome Research Center, Mashhad University of Medical Sciences, Mashhad 13944-91388, Iran
2 shared publications - Hanie Mahaki
Vascular and Endovascular Surgery Research Center Mashhad University of Medical Sciences Mashhad Iran
2 shared publications - Mohsen Sheykhhasan
Cellular and Molecular Research Center, Qom University of Medical Sciences, Qom, Iran
2 shared publications - Naser Kalhor
Department of Mesenchymal Stem Cells
2 shared publications Alireza Dolatshahi-Pirouz
Department of Health Technology, Technical University of Denmark, 2800 Kgs, Lyngby, Denmark
1 shared publication
Latest Publications
- 23 September 2025
- Published by Emerald Publishing in Bioinspired, Biomimetic and Nanobiomaterials
- Vol. 14 (4) , 164-176
Truncated ferritin nanocages: enhanced drug encapsulation and delivery
Nanomedicine has emerged as a promising strategy to mitigate the drawbacks of chemotherapy by enabling targeted drug delivery. Protein nanocages, particularly ferritin, have gained attention due to their unique structural properties and biocompatibility. Herein, the development and characterization of truncated maize ferritin 1 (T-ZmFer1) nanocages for enhanced drug delivery are reported, achieved by removing the E-helix through excision of 17 amino acids from the C-terminus of the protein. T-ZmFer1 was expressed in Escherichia coli Bl21 (DE3) and optimized to enhance soluble protein expression. Purified T-ZmFer1 nanocages exhibited a size of 18.17 nm with a zeta potential of −19.9 mV, indicating well-defined structural characteristics. Drug encapsulation studies revealed a significant increase in encapsulation capacity for T-ZmFer1 nanocages compared to intact ZmFer1 nanocages, with a loading efficiency of ≈76 DOX/protein. Moreover, in vitro drug release profiles demonstrated controlled release kinetics for T-ZmFer1 nanocages, with pH-dependent release behavior. Cytotoxicity assays in SKBR3 cells showed comparable efficacy between DOX-loaded T-ZmFer1 and ZmFer1 nanocages, with T-ZmFer1 nanocages exhibiting superior cytotoxicity at 1 μM DOX concentration. This study underscores the potential of T-ZmFer1 nanocages as versatile drug delivery systems for cancer therapy, offering enhanced biocompatibility and therapeutic efficacy, thus contributing to the advancement of nanomedicine.
- 23 September 2025
- Published by Emerald Publishing in Bioinspired, Biomimetic and Nanobiomaterials
- Vol. 14 (4) , 164-176
Truncated ferritin nanocages: enhanced drug encapsulation and delivery
Nanomedicine has emerged as a promising strategy to mitigate the drawbacks of chemotherapy by enabling targeted drug delivery. Protein nanocages, particularly ferritin, have gained attention due to their unique structural properties and biocompatibility. Herein, the development and characterization of truncated maize ferritin 1 (T-ZmFer1) nanocages for enhanced drug delivery are reported, achieved by removing the E-helix through excision of 17 amino acids from the C-terminus of the protein. T-ZmFer1 was expressed in Escherichia coli Bl21 (DE3) and optimized to enhance soluble protein expression. Purified T-ZmFer1 nanocages exhibited a size of 18.17 nm with a zeta potential of −19.9 mV, indicating well-defined structural characteristics. Drug encapsulation studies revealed a significant increase in encapsulation capacity for T-ZmFer1 nanocages compared to intact ZmFer1 nanocages, with a loading efficiency of ≈76 DOX/protein. Moreover, in vitro drug release profiles demonstrated controlled release kinetics for T-ZmFer1 nanocages, with pH-dependent release behavior. Cytotoxicity assays in SKBR3 cells showed comparable efficacy between DOX-loaded T-ZmFer1 and ZmFer1 nanocages, with T-ZmFer1 nanocages exhibiting superior cytotoxicity at 1 μM DOX concentration. This study underscores the potential of T-ZmFer1 nanocages as versatile drug delivery systems for cancer therapy, offering enhanced biocompatibility and therapeutic efficacy, thus contributing to the advancement of nanomedicine.
- Open Access
- 15 May 2024
- Published by IntechOpen
Recent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of cancer immunotherapy, offering a targeted approach to combat various hematologic malignancies. In this treatment, the patient’s genetically modified T cells are extracted and transformed to produce chimeric antigen receptors (CARs) that are exclusive to cancer cells. These altered T cells identify, attach to, and destroy cancer cells when they are reinfused back into the patient, offering a customized course of therapy. While the CAR T-cell therapy’s clinical success has been most evident in cases of acute lymphoblastic leukemia and certain types of lymphomas, ongoing research aims to extend its applicability to solid tumors. Despite its promise, challenges like cytokine release syndrome and the high cost of treatment remain. Nonetheless, CAR T-cell therapy heralds a new era in cancer treatment, offering a potentially curative approach for patients with otherwise refractory diseases.
- 15 May 2024
- Published by IntechOpen
Open AccessRecent Updates on Chimeric Antigen Receptor T-Cell Approaches in Cancer Immunotherapy
Chimeric antigen receptor (CAR) T-cell therapy is a revolutionary development in the field of cancer immunotherapy, offering a targeted approach to combat various hematologic malignancies. In this treatment, the patient’s genetically modified T cells are extracted and transformed to produce chimeric antigen receptors (CARs) that are exclusive to cancer cells. These altered T cells identify, attach to, and destroy cancer cells when they are reinfused back into the patient, offering a customized course of therapy. While the CAR T-cell therapy’s clinical success has been most evident in cases of acute lymphoblastic leukemia and certain types of lymphomas, ongoing research aims to extend its applicability to solid tumors. Despite its promise, challenges like cytokine release syndrome and the high cost of treatment remain. Nonetheless, CAR T-cell therapy heralds a new era in cancer treatment, offering a potentially curative approach for patients with otherwise refractory diseases.
- Open Access
- 18 May 2023
- Published by Elsevier in Materials Today Bio
- Vol. 20, 100672
Multifunctional nanostructures: Intelligent design to overcome biological barriers
- 18 May 2023
- Published by Elsevier in Materials Today Bio
- Vol. 20, 100672
Open AccessMultifunctional nanostructures: Intelligent design to overcome biological barriers
- Open Access
- 22 December 2022
- Published by MDPI AG in Non-Coding RNA
- Vol. 9 (1) , 1
FLVCR1-AS1 and FBXL19-AS1: Two Putative lncRNA Candidates in Multiple Human Cancers
(1) Background: Mounting evidence supports the idea that one of the most critical agents in controlling gene expression could be long non-coding RNAs (lncRNAs). Upregulation of lncRNA is observed in the different processes related to pathologies, such as tumor occurrence and development. Among the crescent number of lncRNAs discovered, FLVCR1-AS1 and FBXL19-AS1 have been identified as oncogenes in many cancer progression and prognosis types, including cholangiocarcinoma, gastric cancer, glioma and glioblastoma, hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, and osteosarcoma. Therefore, abnormal FBXL19-AS1 and FLVCR1-AS1 expression affect a variety of cellular activities, including metastasis, aggressiveness, and proliferation; (2) Methods: This study was searched via PubMed and Google Scholar databases until May 2022; (3) Results: FLVCR1-AS1 and FBXL19-AS1 participate in tumorigenesis and have an active role in impacting several signaling pathways that regulate cell proliferation, migration, invasion, metastasis, and EMT; (4) Conclusions: Our review focuses on the possible molecular mechanisms in a variety of cancers regulated by FLVCR1-AS1 and FBXL19-AS1. It is not surprising that there has been significant interest in the possibility that these lncRNAs might be used as biomarkers for diagnosis or as a target to improve a broader range of cancers in the future.
- 22 December 2022
- Published by MDPI AG in Non-Coding RNA
- Vol. 9 (1) , 1
Open AccessFLVCR1-AS1 and FBXL19-AS1: Two Putative lncRNA Candidates in Multiple Human Cancers
(1) Background: Mounting evidence supports the idea that one of the most critical agents in controlling gene expression could be long non-coding RNAs (lncRNAs). Upregulation of lncRNA is observed in the different processes related to pathologies, such as tumor occurrence and development. Among the crescent number of lncRNAs discovered, FLVCR1-AS1 and FBXL19-AS1 have been identified as oncogenes in many cancer progression and prognosis types, including cholangiocarcinoma, gastric cancer, glioma and glioblastoma, hepatocellular carcinoma, lung cancer, ovarian cancer, breast cancer, colorectal cancer, and osteosarcoma. Therefore, abnormal FBXL19-AS1 and FLVCR1-AS1 expression affect a variety of cellular activities, including metastasis, aggressiveness, and proliferation; (2) Methods: This study was searched via PubMed and Google Scholar databases until May 2022; (3) Results: FLVCR1-AS1 and FBXL19-AS1 participate in tumorigenesis and have an active role in impacting several signaling pathways that regulate cell proliferation, migration, invasion, metastasis, and EMT; (4) Conclusions: Our review focuses on the possible molecular mechanisms in a variety of cancers regulated by FLVCR1-AS1 and FBXL19-AS1. It is not surprising that there has been significant interest in the possibility that these lncRNAs might be used as biomarkers for diagnosis or as a target to improve a broader range of cancers in the future.